Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma
IRF-4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF-4 expression. IRF-4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti-CD38 therapy.
Authors
- Yuhong Zhong (ORCID: https://orcid.org/0000-0001-6204-5827)
- Qianwen Hu (ORCID: https://orcid.org/0000-0002-3889-6434)
- Chao Qi (ORCID: https://orcid.org/0000-0002-0826-2334)
- Sai Qiao
- Xiaofen Wang (ORCID: https://orcid.org/0000-0003-0903-2044)
- Suwen Yang (ORCID: https://orcid.org/0000-0002-6295-5545)
- Hong Jin (ORCID: https://orcid.org/0009-0003-4053-009X)
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- International Journal of Laboratory Hematology
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1111/ijlh.14366
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45